세파크롤(Cefaclor) 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 판매채널별, 최종 용도별, 지역별, 경쟁별(2020-2030년)
Cefaclor Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sales Channel, By End Use, By Region and Competition, 2020-2030F
상품코드:1703428
리서치사:TechSci Research
발행일:2025년 04월
페이지 정보:영문 185 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세파크롤 세계 시장 규모는 2024년 4억 1,819만 달러에서 2030년에는 5억 8,330만 달러에 달할 것으로 예상되며, 예측 기간 동안 연평균 성장률(CAGR)은 3.77%를 보일 것으로 예측됩니다.
이러한 꾸준한 시장 성장은 호흡기 감염, 요로 감염, 피부 감염 및 기타 세균성 질환의 치료에 일반적으로 처방되는 세파크롤(2세대 세팔로스포린계 항생제)의 광범위한 사용으로 뒷받침되고 있습니다. 세파크롤의 광범위한 효능, 우수한 안전성 프로파일, 확립된 임상적 유용성은 외래 환자 치료 환경에서 세파크롤의 강력한 포지셔닝을 뒷받침하고 있습니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
4억 1,819만 달러
시장 규모 : 2030년
5억 8,330만 달러
CAGR : 2025-2030년
3.77%
급성장 부문
직접
최대 시장
아시아태평양
세계 세균 감염률 증가, 헬스케어에 대한 인식 증가, 신흥국 시장을 중심으로 한 항생제 접근성 향상으로 시장 개척은 더욱 가속화되고 있습니다. 특히 아시아태평양과 라틴아메리카 시장은 헬스케어 인프라 구축과 도시화에 힘입어 수요가 가속화되고 있습니다. 반면 북미와 유럽은 의약품 유통망이 잘 갖춰져 있고 처방량도 안정적이어서 성숙한 시장을 유지하고 있습니다.
이러한 긍정적인 추세에도 불구하고, 세파크롤 시장은 주목할 만한 문제에 직면해 있습니다. 그 중 가장 중요한 것은 항균제 내성(AMR)에 대한 우려 증가와 엄격한 항생제 스튜어드십 프로토콜을 시행해야 한다는 규제 당국의 압력입니다. 전 세계 보건 당국은 항생제 내성균의 출현에 대응하기 위해 항생제 사용을 엄격하게 관리하고 있습니다. 이러한 노력은 공중 보건을 보호하는 데 중요하지만, 세파크롤의 처방 빈도에 영향을 미쳐 새로운 대체 항균제 개발 및 채택을 촉진할 수 있습니다.
Global Cefaclor market was valued at USD 418.19 million in 2024 and is projected to reach USD 583.30 million by 2030, expanding at a compound annual growth rate (CAGR) of 3.77% over the forecast period. This steady market growth is underpinned by the widespread use of cefaclor-a second-generation cephalosporin antibiotic-commonly prescribed for the treatment of respiratory tract infections, urinary tract infections, skin infections, and other bacterial conditions. Cefaclor's broad-spectrum efficacy, favorable safety profile, and established clinical utility continue to support its strong positioning in outpatient therapeutic settings.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 418.19 Million
Market Size 2030
USD 583.30 Million
CAGR 2025-2030
3.77%
Fastest Growing Segment
Direct
Largest Market
Asia-Pacific
Market growth is further reinforced by the rising global incidence of bacterial infections, increasing healthcare awareness, and enhanced access to antibiotics-particularly in developing regions. Notably, markets in Asia-Pacific and Latin America are experiencing accelerated demand, driven by improvements in healthcare infrastructure and urbanization. Meanwhile, North America and Europe maintain mature markets due to well-established pharmaceutical distribution networks and stable prescription volumes.
Despite these favorable trends, the cefaclor market faces notable challenges. Chief among them are the growing concerns surrounding antimicrobial resistance (AMR) and regulatory pressures to implement stringent antibiotic stewardship protocols. Health authorities across the globe are enforcing tighter controls on antibiotic use to counter the emergence of resistant bacterial strains. While these initiatives are critical for safeguarding public health, they may impact the prescribing frequency of cefaclor and incentivize the development and adoption of newer antimicrobial alternatives.
Key Market Drivers
Healthcare Sector Expansion
The continued expansion of the global healthcare sector remains a key driver of cefaclor market growth. The global hospital market is projected to generate approximately USD 4.41 trillion in revenue by 2025, with the United States expected to contribute USD 1.55 trillion. In parallel, U.S. hospitals are significantly investing in telemedicine to broaden healthcare access-especially in rural and underserved communities.
Emerging economies are witnessing similar trends, with growing investments in healthcare infrastructure fueling demand for widely used antibiotics such as cefaclor. For instance, India's Union Budget 2025-26 allocated USD 11.50 billion toward healthcare, emphasizing system development and capacity building. The government also plans to launch a USD 6.80 billion credit incentive scheme to attract further investments into healthcare infrastructure.
These public and private sector investments are facilitating the expansion of hospitals, diagnostic services, and healthcare personnel. As access to medical care improves-particularly in previously underserved regions-diagnosis and treatment rates are rising, thereby driving higher prescription volumes of broad-spectrum antibiotics like cefaclor.
Key Market Challenges
Rising Antimicrobial Resistance (AMR)
The global escalation of antimicrobial resistance (AMR) presents a significant barrier to the growth of the cefaclor market. Resistance among bacterial strains is reducing the clinical effectiveness of widely used antibiotics, including second-generation cephalosporins such as cefaclor. This trend not only compromises treatment outcomes but also dampens overall demand for the drug.
AMR has become a major global health concern, fueled by the overuse and inappropriate prescription of antibiotics in both human healthcare and agriculture. In many regions, antibiotics like cefaclor are frequently administered without adequate diagnostic justification or are misused for viral infections, accelerating the emergence of resistant strains. Consequently, the therapeutic reliability of cefaclor for treating infections such as bronchitis, otitis media, and urinary tract infections is increasingly being called into question.
Key Market Trends
Rising Incidence of Bacterial Infections
The increasing prevalence of bacterial infections represents a significant trend shaping the cefaclor market. The 2024 WHO Bacterial Priority Pathogens List (BPPL) highlights 24 high-risk pathogens across 15 bacterial families, including Gram-negative bacteria resistant to last-resort antibiotics and drug-resistant strains such as Mycobacterium tuberculosis, Salmonella, Shigella, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Staphylococcus aureus.
These pathogens have been identified as global threats due to their high transmission potential, limited treatment options, and widespread burden. In this context, cefaclor continues to be a vital therapeutic agent, especially in addressing respiratory tract infections, skin infections, otitis media, and urinary tract infections.
The surge in treatable respiratory infections-such as pharyngitis, bronchitis, and pneumonia-is particularly notable among pediatric and elderly populations, where immune vulnerability is greater. As healthcare systems respond to seasonal infection cycles and the ongoing repercussions of recent viral pandemics, the demand for reliable, broad-spectrum antibiotics like cefaclor remains robust.
Key Market Players
ACS DOBFAR
Qilu Antibiotics Pharmaceutical
Zhejiang Anglikang Pharmaceutical Co., Ltd.
Zhejiang Dongbang Pharmaceutical Co., Ltd.
Zhejiang East Asia Pharmaceutical Co., Ltd.
Zhejiang Zhebang Pharmaceutical Co., Ltd
Centrient Pharmaceuticals (Zibo)
Conscientia Industrial Co., Ltd
Dhanuka Laboratories Ltd.
Lupin Limited
Report Scope
In this report, the Global Cefaclor Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Cefaclor Market, By Sales Channel:
Direct
Indirect
Cefaclor Market, By End Use:
Lung Infection
Skin Infection
Ear Infection
Throat Infection
Tonsils
Urinary Tract Infection
Others
Cefaclor Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Cefaclor Market.
Available Customizations:
Global Cefaclor Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends
4. Impact of COVID-19 on Global Cefaclor Market
5. Global Cefaclor Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Sales Channel (Direct, Indirect)
5.2.2. By End Use (Lung Infection, Skin Infection, Ear Infection, Throat Infection, Tonsils, Urinary Tract Infection, Others)
5.2.3. By Region
5.2.4. By Company (2024)
5.3. Market Map
6. North America Cefaclor Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Sales Channel
6.2.2. By End Use
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Cefaclor Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Sales Channel
6.3.1.2.2. By End Use
6.3.2. Mexico Cefaclor Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Sales Channel
6.3.2.2.2. By End Use
6.3.3. Canada Cefaclor Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Sales Channel
6.3.3.2.2. By End Use
7. Europe Cefaclor Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Sales Channel
7.2.2. By End Use
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. France Cefaclor Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Sales Channel
7.3.1.2.2. By End Use
7.3.2. Germany Cefaclor Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Sales Channel
7.3.2.2.2. By End Use
7.3.3. United Kingdom Cefaclor Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Sales Channel
7.3.3.2.2. By End Use
7.3.4. Italy Cefaclor Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Sales Channel
7.3.4.2.2. By End Use
7.3.5. Spain Cefaclor Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Sales Channel
7.3.5.2.2. By End Use
8. Asia Pacific Cefaclor Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Sales Channel
8.2.2. By End Use
8.2.3. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Cefaclor Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Sales Channel
8.3.1.2.2. By End Use
8.3.2. India Cefaclor Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Sales Channel
8.3.2.2.2. By End Use
8.3.3. South Korea Cefaclor Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Sales Channel
8.3.3.2.2. By End Use
8.3.4. Japan Cefaclor Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Sales Channel
8.3.4.2.2. By End Use
8.3.5. Australia Cefaclor Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Sales Channel
8.3.5.2.2. By End Use
9. South America Cefaclor Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Sales Channel
9.2.2. By End Use
9.2.3. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Cefaclor Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Sales Channel
9.3.1.2.2. By End Use
9.3.2. Argentina Cefaclor Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Sales Channel
9.3.2.2.2. By End Use
9.3.3. Colombia Cefaclor Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Sales Channel
9.3.3.2.2. By End Use
10. Middle East and Africa Cefaclor Market Outlook
